Serotonin Syndrome With Standard-Dose Vilazodone (Viibryd) Monotherapy

Taylor W. Butler, Robert A. Lucas, Wahid Barghouthy


There is a deficiency in published literature describing serotonin syndrome with standard vilazodone (Viibryd<sup></sup>) treatment. This is the case of a 28-year-old female with anxiety treated with vilazodone. Prior to the initiation of vilazodone, vital signs were normal and the patient exhibited no signs of excessive serotonin. The patient was prescribed vilazodone with the appropriate 2-week titration per the FDA-approved prescribing information. During the first week, the patient reported excessive perspiration and gastrointestinal symptoms. On day 17 of vilazodone therapy, the patient reported a major neurologic reaction and discontinued vilazodone. The patient was diagnosed with possible serotonin syndrome. Symptoms of elevated serotonin, including hyperhidrosis and nausea, did not resolve until 2 weeks after discontinuation of therapy. In this case, the patient developed early warning signs of excessive serotonin in the periphery and eventually a potential life-threatening neurologic adverse event on vilazodone monotherapy. Practitioners should counsel on early warning signs of excessive serotonin and the potential for serotonin syndrome, even with a single serotonergic agent.

J Med Cases. 2014;5(11):567-569


Serotonin; Serotonin syndrome; Vilazodone; Monotherapy; Psychopharmacology; Neuropharmacology

Full Text: HTML PDF

Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website:   editorial contact:
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.